Esomeprazole for prevention and resolution of upper gastrointestinal symptoms in patients treated with low-dose acetylsalicylic acid for cardiovascular protection: The oberon trial

Journal of Cardiovascular Pharmacology

Volumn 61, Issue 3, 2013, Pages 250-257

  Scheiman, James M ^a   Herlitz, Johan ^b   Veldhuyzen Van Zanten, Sander J ^c   Lanas, Angel ^d   Agewall, Stefan ^e   Nauclér, Emma C ^f   Svedberg, Lars Erik ^f   Nagy, Péter ^f  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF BORÅS   (Sweden)

^c UNIVERSITY OF ALBERTA   (Canada)

^d HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^e ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^f ASTRAZENECA R AND D   (Sweden)

Author keywords

esomeprazole; low dose acetylsalicylic acid; upper gastrointestinal symptoms

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; ESOMEPRAZOLE; NITRATE; PLACEBO;

AGED; ANTICOAGULANT THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DIGESTIVE SYSTEM ULCER; DRUG EFFICACY; DYSPEPSIA; FEMALE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL REFLUX; GASTROINTESTINAL SYMPTOM; HIGH RISK POPULATION; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); PEPTIC ULCER; POST HOC ANALYSIS; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; REFLUX ESOPHAGITIS; SELF REPORT; SEX DIFFERENCE; STOMACH ULCER; TREATMENT DURATION; UPPER GASTROINTESTINAL SYMPTOM;

AGE FACTORS; AGED; ANTI-ULCER AGENTS; ASPIRIN; CARDIOVASCULAR DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DYSPEPSIA; ESOMEPRAZOLE; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASES; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; RECURRENCE; RISK FACTORS; SELF REPORT; UPPER GASTROINTESTINAL TRACT;

EID: 84875224065     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31827cb626     Document Type: Article

References (23)

1. U.S. Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;150:396-404.
2. Pearson TA, Blair SN, Daniels SR, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association science advisory and coordinating committee. Circulation. 2002;106:388-391.
3. Lanas A, Scheiman J. Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment. Curr Med Res Opin. 2007; 23:163-173.
4. Tournoij E, Peters RJ, Langenberg M, et al. The prevalence of intolerance for low-dose acetylsalicylacid in the secondary prevention of atherothrombosis. Eur J Vasc Endovasc Surg. 2009;37:597-603.
5. Cayla G, Collet JP, Silvain J, et al. Prevalence and clinical impact of upper gastrointestinal symptoms in subjects treated with low dose aspirin: the UGLA survey. Int J Cardiol. 2012;156:69-75.
6. Hernández-Díaz S, García Rodríguez LA. Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications. BMC Med. 2006;4:22.
7. Herlitz J, Tóth PP, Næsdal J. Low-dose aspirin therapy for cardiovascular prevention: quantification and consequences of poor compliance or discontinuation. Am J Cardiovasc Drugs. 2010;10:125-141.
8. Moberg C, Næsdal J, Svedberg LE, et al. Impact of gastrointestinal problems on adherence to low-dose acetylsalicylic acid: a quantitative study in patients with cardiovascular risk. Patient. 2011;4:103-113.
9. Pratt S, Thompson VJ, Elkin EP, et al. The impact of upper gastrointestinal symptoms on nonadherence to, and discontinuation of, low-dose acetylsalicylic acid in patients with cardiovascular risk. Am J Cardiovasc Drugs. 2010;10:281-288.
10. García Rodríguez LA, Cea Soriano L, Hill C, et al. Increased risk of stroke after discontinuation of acetylsalicylic acid: a UK primary care study. Neurology. 2011;76:740-746.
11. García Rodríguez LA, Cea Soriano L, Martín Merino E, et al. Discontinuation of low dose aspirin and risk of myocardial infarction: case- control study in UK primary care. BMJ. 2011;343:d4094.
12. Biondi-Zoccai GG, Lotrionte M, Agostoni P, et al. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J. 2006;27:2667-2674.
13. Abraham NS, Hlatky MA, Antman EM, et al. ACCF/ACG/AHA 2010 Expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/ AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol. 2010; 105:2533-2549.
14. Hamm CW, Bassand JP, Agewall S, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2011;32:2999-3054.
15. Cea Soriano L, Bueno H, Johansson S, et al. Predictors and time trends in clopidogrel and proton pump inhibitor coprescription with low-dose acetylsalicylic acid. Pharmacoepidemiol Drug Saf. 2012; 21:463-469.
16. Scheiman JM, Devereaux PJ, Herlitz J, et al. Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomised, controlled trial (OBERON). Heart. 2011;97:797-802.
17. Yeomans N, Lanas A, Labenz J, et al. Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am J Gastroenterol. 2008;103:2465-2473.
18. Shaw MJ, Talley NJ, Beebe TJ, et al. Initial validation of a diagnostic questionnaire for gastroesophageal reflux disease. Am J Gastroenterol. 2001;96:52-57.
19. Vakil N, Veldhuyzen van Zanten S, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101:1900-1920.
20. McQuaid KR, Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med. 2006;119:624-638.
21. Niv Y, Battler A, Abuksis G, et al. Endoscopy in asymptomatic minidose aspirin consumers. Dig Dis Sci. 2005;50:78-80.
22. Lanas A, García Rodríguez LA, Arroyo MT, et al. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol. 2007;102:507-515.
23. Gelfond M, Rozen P, Keren S, et al. Effect of nitrates on LOS pressure in achalasia: a potential therapeutic aid. Gut. 1981;22:312-318.